Parkinson’s disease Pipeline Insight 2020 by DelveInsight

 Breaking News
  • No posts were found

Parkinson’s disease Pipeline Insight 2020 by DelveInsight

September 03
13:26 2020
Parkinson's disease Pipeline Insight 2020 by DelveInsight

(Albany, US) DelveInsight has launched a new report on Parkinson’s Disease Pipeline


Parkinson’s Disease Pipeline Insight, 2020″ report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Parkinson’s Disease market. A detailed picture of the Parkinson’s Disease pipeline landscape is provided, which includes the disease overview and Parkinson’s Disease treatment guidelines. The assessment part of the report embraces in-depth Parkinson’s Disease commercial assessment and clinical assessment of the Parkinson’s Disease pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Parkinson’s Disease collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.


Parkinson’s disease is a type of movement disorder that can affect the ability to perform common, daily activities. The most common motor symptoms of PD are tremor (a form of rhythmic shaking), stiffness or rigidity of the muscles, and slowness of movement (called bradykinesia). Most of the people develop the symptoms of Parkinson’s after the age of 50, but it can affect younger person as well. There are mainly two types of Parkinson’s, Primary Parkinsonism or Idiopathic Parkinson’s and Secondary or atypical Parkinsonism. According to the American Parkinson Disease Association (APDA), Parkinson’s disease Handbook, 2019, around 1 million individuals in the US have PD in 2019 and it increases with age, the similar trend was seen in the study by Marras, C et al., which was conducted in 2018. As per Delveinsight’s estimation, the disease is more frequent in people age ≥75 years (47%) followed by people aged 65–74 years (35%), 50–64 years of age. It was also found that Parkinson’s is less frequent in people age ≤49 years. Also as per, Parkinson’s UK most people with Parkinsonism have idiopathic Parkinson’s disease, and the data from Parkinson’s News Today also confirmed that the majority of patients (around 80–85%) diagnosed with Parkinson’s disease have what is called primary parkinsonism or idiopathic Parkinson’.


View Free Sample Page: –


Parkinson’s disease Pipeline


Some pharmaceutical and biotech companies like Prevail Therapeutics, Axovant Gene Therapies, Neurocrine Biosciences/Voyager Therapeutics, Denali Therapeutics, and others are researching new therapies that target other aspects of pathology, namely genetic mutations, and Lewy bodies (a hallmark feature of Parkinson’s disease). Apart from these, other small molecule that are under development and expected to enter the market includes Istradefylline (Kyowa Kirin), Opicapone (Neurocrine Biosciences), P2B001 (Pharma Two B Ltd), LY03003 (Luye Pharma), ABBV-951 (AbbVie), APL-130277 (Sunovion Pharma), Accordion Pill (Intec Pharma), Apomorphine infusion (US WorldMeds LLC), IPX203 (Impax Laboratories), IRL752 (Integrative Research Laboratories AB), ND0612 (NeuroDerm), ITI-214 (Intra-Cellular Therapies), Nilotinib (Novartis), etc. The expected launch of these therapies during the forecasted period are expected to impact the market size of Parkinson’s disease (PD) in the upcoming years. Neurocrine Biosciences is developing a new gene therapy VY-AADC, which is currently being evaluated in patients who have been diagnosed with Parkinson’s disease for at least 4 years, are not responding adequately to oral medications, and have at least 3 hours of “off” time during the day, as measured by a validated self-reported patient diary. It is developed by Neurocrine Biosciences and Voyager Therapeutics as part of strategic collaboration. Istradefylline (Nouriast) is a selective agonist at the A2A receptor that is administered orally. It reduces dyskinesia resulting from long-term treatment with classical anti-parkinson drugs such as levodopa. The drug is already approved in Japan in 2013, and the company has filed a new drug application for its approval in the US. Opicapone (Ongentys) is a new long-acting, peripherally selective, oncedaily catechol-O-methyl transferase inhibitor. Opicapone is licensed in Europe for the treatment of Parkinson’s disease. Neurocrine has filed an application for its approval in the US. APL-130277 is a novel formulation of apomorphine and a dopamine agonist, is being developed for the on-demand management of OFF episodes associated with Parkinson’s disease (PD). It is an under-the-tongue (sublingual) apomorphine film that may be easier for patients to take. The U.S. Food and Drug Administration has accepted Sunovion‘s resubmitted new drug application (NDA) for APL-130277 for treating off episodes in Parkinson’s disease.


Marketed Drugs included in the report

  • Istradefylline (KW6002): Kyowa Kirin
  • Opicapone: BIAL
  • Gocovri: Adamas Pharmaceuticals
  • Xadago: Zambon SpA
  • Osmolex ER: Osmotica Pharmaceutical
  • Duopa (Duodopa, ABT-SLV187): AbbVie
  • Rytary: Impax Laboratories
  • Inbrija: Acorda Therapeutics
  • ·         Nuplazid: ACADIA Pharmaceuticals Inc


Emerging therapies included in the report

  • Apomorphine Infusion: US WorldMeds LLC
  • Accordion Pill Carbidopa/Levodopa: Intec Pharma
  • APL–130277: Sunovion Pharma
  • P2B001: Pharma Two B Ltd
  • IPX203: Impax Laboratories
  • LY03003: Luye Pharma
  • ABBV-951: AbbVie
  • NTCELL Implantation: Living Cell Technologies
  • Nilotinib: Novartis
  • Solriamfetol (JZP-110): Jazz Pharmaceuticals
  • VY-AADC: Neurocrine Biosciences/Voyager Therapeutics


Parkinson’s disease Report Scope

  • The Parkinson’s disease report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Parkinson’s disease across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Parkinson’s Disease therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Parkinson’s disease research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Parkinson’s disease.


Download free sample page:-


Table of content

1. Report Introduction

2. Parkinson’s Disease 

3. Parkinson’s Disease Current Treatment Patterns

4. Parkinson’s Disease – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Parkinson’s Disease Late Stage Products (Phase-III)

7. Parkinson’s Disease Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Parkinson’s Disease Discontinued Products

13. Parkinson’s Disease Product Profiles

14. Parkinson’s Disease Key Companies

15. Parkinson’s Disease Key Products

16. Dormant and Discontinued Products

17. Parkinson’s Disease Unmet Needs

18. Parkinson’s Disease Future Perspectives

19. Parkinson’s Disease Analyst Review  

20. Appendix

21. Report Methodology


Related Reports



About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Contact Us

Shruti Thakur

[email protected]



Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

Related Articles